53
person
Eileen Murray
person
Deb Liu
Deb Liu is the President and CEO of Ancestry. With over 19 years in the tech industry, she has be
en named one of Business Insider’s most powerful female engineers and one of PaymentsSource’smost influential women in payments.
+ Read More
person
Sébastien Eisinger
staff
Jessica Marshall
Jessica Marshall is an associate at FasterCures.
staff
Nicole Valentine
Nicole Valentine is the director, FinTech at the Milken Institute with over a decade of fina
ncial services, international mergers and acquisitions, technology, and innovation experience.
+ Read More
staff
Christina Dialynas
Christina Dialynas is an associate director at the Milken Institute, Public Health. Prior to join
ing the Center for Public Health, Christina worked on the Milken Institute’s Business and Program Development team as their project manager.
+ Read More
person
Michael Lin, PhD
Dr. Michael Cheng-Yi Lin was a Regional Economist within the Research Department at the Milken In
stitute.
+ Read More
person
Aaron Melaas
report
Promoting Participation in SME Boards Through Tax Incentives: A Global Overview
Over the last two decades, a large number of stock exchanges have established dedicated market segm
ents for small and medium-sized enterprises (SMEs).
+ Read More
report
SMEs and Public Equity Financing: A New Dataset of SME Boards in Emerging-Market and Developing Economies
In recent years, a number of stock exchanges in emerging-market and developing economies have estab
lished dedicated market segments for small and medium-sized enterprises (SMEs).
+ Read More
report
Financing Models to Expand Access to Electric Vehicles in California
California accelerated the adoption rate of electric vehicles (EVs) through rebates and other opera
tional incentives. However, due to socioeconomic lifestyle burdens, disadvantaged communities have not had full access to these efforts.
+ Read More
report
Policy Issue Brief: A Call to Action for Diversity in Clinical Trials
FasterCures has initiated a body of work to advance system change within biomedical research to foc
us on and value diversity and representation within clinical trials.
+ Read More